Table 6.

Treatment patterns among overall cohort of patients with COPD

		Year 1			Year 2		Year 3		Year 4
		Patients (n, Not Unique)	% of Total Cohort	% of All Year 1 Claims	Patients (n, Not Unique)	% of All Year 2 Claims	Patients (n, Not Unique)	% of All Year 3 Claims	Patients (n, Not Unique)	% of All Year 4 Claims
Group	ICS	39,093	16.4	14.7	34,826	14.5	32,751	13.8	28,977	13.2
	LABA Monotherapy	1,218	0.5	0.4	1,035	0.5	1,882	0.7	3,968	1.4
	LAMA Monotherapy	23,661	9.9	12.1	19,905	11.8	18,063	11.2	16,295	10.5
	LABA + ICS	43,667	18.3	21.4	38,299	21.9	36,230	21.4	33,518	20.5
	LAMA + LABA	5,941	2.5	2.4	6,863	3.4	7,759	4.2	7,842	4.6
	LABA + LAMA+ ICS	103	0.0	0.0	702	0.2	2,387	1.0	4,022	2.1
	Methylxanthine Monotherapy	927	0.4	0.5	833	0.5	714	0.5	614	0.4
	PDE Monotherapy	472	0.2	0.3	495	0.3	558	0.3	622	0.4
	SABA Monotherapy	91,418	38.4	39.6	75,805	38.6	71,640	38.7	65,606	39.1
	SAMA Monotherapy	6,838	2.9	2.4	5,720	2.3	5,324	2.2	4,676	2.0
	SAMA + SABA	17,031	7.2	6.1	13,869	6.0	13,705	6.0	12,259	5.8

COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; LAMA: long-acting muscarinic antagonist; PDE: phosphodiesterase; SABA: short-acting beta-agonist; SAMA: short-acting muscarinic antagonist